Trial Profile
A phase 1 and 2, randomized open-label study to evaluate the pharmacokinetics, safety and antiretroviral activity of succinylated human serum albumin (Suc-HSA) in treatment naive HIV-1 infected subjects
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Succinylated human serum albumin (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 13 Nov 2006 Status change
- 18 Nov 2005 New trial record.